Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Karp, Judith E., Vener, Tatiana I., Raponi, Mitch, Ritchie, Ellen K., Smith, B. Douglas, Gore, Steven D., Morris, Lawrence E., Feldman, Eric J., Greer, Jacqueline M., Malek, Sami, Carraway, Hetty E., Ironside, Valerie, Galkin, Steven, Levis, Mark J., McDevitt, Michael A., Roboz, Gail R., Gocke, Christopher D., Derecho, Carlo, Palma, John, Wang, Yixin, Kaufmann, Scott H., Wright, John J., Garret-Mayer, Elizabeth
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3251236/
https://ncbi.nlm.nih.gov/pubmed/22001391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-08-370825
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados